{"component": "definition", "props": {"groups": [{"samples": [{"hash": "8tGSlUg3OpM", "uri": "https://www.uregni.gov.uk/files/uregni/media-files/2019-04-11%20Annex%20B%20GNI%20UK%20licence%20modifications.pdf", "label": "www.uregni.gov.uk", "score": 14.0494842529, "published": false}, {"hash": "gXiDSP46WR4", "uri": "https://www.uregni.gov.uk/sites/uregni/files/media-files/BGTL%20Licence%20Updated%2031%2008%202018.pdf", "label": "www.uregni.gov.uk", "score": 10.1704311371, "published": false}, {"hash": "e3PcdNcu325", "uri": "https://www.uregni.gov.uk/sites/uregni.gov.uk/files/media-files/2016-09-01_PTL_licence_for_conveyance_of_gas_in_NI_-_Final.pdf", "label": "www.uregni.gov.uk", "score": 10.1704311371, "published": false}], "snippet": "means the annual product multiplier and/or seasonal factor as appropriate for Gas Year \u201ct\u201d, in accordance with the Gas Product Multipliers and Time Factors Table.", "snippet_links": [{"key": "the-annual", "type": "clause", "offset": [6, 16]}, {"key": "gas-year", "type": "definition", "offset": [78, 86]}, {"key": "in-accordance-with", "type": "definition", "offset": [92, 110]}, {"key": "time-factors", "type": "clause", "offset": [143, 155]}], "size": 23, "hash": "8b97d11cc84a261258e9aac4653e2d39", "id": 1}, {"samples": [{"hash": "70O3X6zLR1p", "uri": "/contracts/70O3X6zLR1p#pma", "label": "Standard Terms and Conditions for Channel Access", "score": 33.4752006531, "published": true}, {"hash": "43omDHqzNmh", "uri": "/contracts/43omDHqzNmh#pma", "label": "Standard Terms and Conditions for Owners Berthing at Port of Melbourne Dedicated Facilities", "score": 33.4752006531, "published": true}, {"hash": "iM3GBvJ8gft", "uri": "/contracts/iM3GBvJ8gft#pma", "label": "Standard Terms and Conditions", "score": 33.0139846802, "published": true}], "snippet": "means the Port Management Act 1995 (Vic) as amended from time to time.", "snippet_links": [{"key": "management-act", "type": "definition", "offset": [15, 29]}, {"key": "as-amended", "type": "definition", "offset": [41, 51]}, {"key": "from-time-to-time", "type": "clause", "offset": [52, 69]}], "size": 14, "hash": "c754a8ccddd66074e0052179a758281f", "id": 2}, {"samples": [{"hash": "gIrfouzyXxs", "uri": "http://www.state.wv.us/admin/PURCHASE/Bids/FY2025/B_0215_AVN2500000001_02.pdf", "label": "www.state.wv.us", "score": 11.8800697327, "published": false}, {"hash": "43W1mIT4UxW", "uri": "http://fsims.faa.gov/wdocs/Orders/2150_3B.htm", "label": "fsims.faa.gov", "score": 10.1704311371, "published": false}, {"hash": "4T07wGrlkF9", "uri": "https://www.faa.gov/documentLibrary/media/Order/ND/2150.3B.pdf", "label": "www.faa.gov", "score": 4.0, "published": false}], "snippet": "means Parts Manufacturer Approval.", "snippet_links": [{"key": "parts-manufacturer-approval", "type": "definition", "offset": [6, 33]}], "size": 12, "hash": "4d9ec6419d00714ca0a911dc8c9fdff5", "id": 3}, {"samples": [{"hash": "5yaHcwwVXW7", "uri": "/contracts/5yaHcwwVXW7#pma", "label": "Master Collaboration Agreement (Syros Pharmaceuticals, Inc.)", "score": 33.3696098328, "published": true}, {"hash": "8dRkcmZEfwW", "uri": "/contracts/8dRkcmZEfwW#pma", "label": "Master Collaboration Agreement (Blueprint Medicines Corp)", "score": 27.8583164215, "published": true}, {"hash": "9lF4MR7GX4G", "uri": "https://ir.blueprintmedicines.com/static-files/cc0bcdac-d225-4879-b4e6-18cb71490a5d", "label": "ir.blueprintmedicines.com", "score": 9.5147161484, "published": false}], "snippet": "means Pre-Market Approval as defined by FDA.", "snippet_links": [{"key": "market-approval", "type": "definition", "offset": [10, 25]}], "size": 12, "hash": "e80db58166c132338bf2e44b0d5876e2", "id": 4}, {"samples": [{"hash": "7TilYFrfug6", "uri": "/contracts/7TilYFrfug6#pma", "label": "Purchase and Support Agreement (Jetblue Airways Corp)", "score": 37.1149902344, "published": true}, {"hash": "j6gRlsklLdM", "uri": "/contracts/j6gRlsklLdM#pma", "label": "Purchase and Support Agreement (Jetblue Airways Corp)", "score": 36.1211509705, "published": true}, {"hash": "aBJoVFswzlF", "uri": "/contracts/aBJoVFswzlF#pma", "label": "Engine Purchase and Support Agreement (Frontier Group Holdings, Inc.)", "score": 32.1813812256, "published": true}], "snippet": "or \u201cParts Manufacturer Approval\u201d means the authority granted by the FAA to manufacture parts for installation in type-certificated products.", "snippet_links": [{"key": "parts-manufacturer-approval", "type": "definition", "offset": [4, 31]}, {"key": "granted-by", "type": "definition", "offset": [53, 63]}, {"key": "to-manufacture", "type": "definition", "offset": [72, 86]}], "size": 11, "hash": "07b0b3625ed2d5e108851235a738f543", "id": 5}, {"samples": [{"hash": "f2Sb3f2oPs0", "uri": "/contracts/f2Sb3f2oPs0#pma", "label": "Master Collaboration Agreement (Blueprint Medicines Corp)", "score": 27.5544147491, "published": true}, {"hash": "b33ZmgUiEdk", "uri": "/contracts/b33ZmgUiEdk#pma", "label": "Master Collaboration Agreement (Blueprint Medicines Corp)", "score": 27.3545513153, "published": true}, {"hash": "hYv4O2KFXVI", "uri": "https://ir.blueprintmedicines.com/static-files/a3499f44-b882-4d55-adaa-01e021d25409", "label": "Amendment", "score": 13.9952087402, "published": false}], "snippet": "means: (i) a U.S. pre-market approval application for a Class III medical device, including all information submitted with or incorporated by reference, or (ii) any analogous application to those set forth in (i) that is filed with the relevant Regulatory Authority in a country or region in the Markets, including any supplemental applications.", "snippet_links": [{"key": "a-us", "type": "clause", "offset": [11, 16]}, {"key": "approval-application", "type": "definition", "offset": [29, 49]}, {"key": "class-iii", "type": "definition", "offset": [56, 65]}, {"key": "medical-device", "type": "clause", "offset": [66, 80]}, {"key": "information-submitted", "type": "clause", "offset": [96, 117]}, {"key": "incorporated-by-reference", "type": "definition", "offset": [126, 151]}, {"key": "relevant-regulatory-authority", "type": "definition", "offset": [236, 265]}], "size": 11, "hash": "3a9ccb76a2949b8107b23b1e338e30d9", "id": 6}, {"samples": [{"hash": "gGBL59iUiJq", "uri": "/contracts/gGBL59iUiJq#pma", "label": "Component Services and Pooling Agreement", "score": 31.3408622742, "published": true}, {"hash": "4YyhoKmDDh2", "uri": "/contracts/4YyhoKmDDh2#pma", "label": "Distribution Services Agreement", "score": 31.3408622742, "published": true}, {"hash": "2cYO1HYHW0p", "uri": "/contracts/2cYO1HYHW0p#pma", "label": "Component Services and Pooling Agreement (Controladora Vuela Compania De Aviacion, S.A.B. De C.V.)", "score": 24.4661197662, "published": true}], "snippet": "means Parts Manufacturing Approval.", "snippet_links": [{"key": "manufacturing-approval", "type": "definition", "offset": [12, 34]}], "size": 9, "hash": "b15693891aa1558d58ba8e18039ba375", "id": 7}, {"samples": [{"hash": "1F21383CoQq", "uri": "/contracts/1F21383CoQq#pma", "label": "Collaboration Agreement (Celldex Therapeutics, Inc.)", "score": 21.1916503906, "published": true}, {"hash": "avZHGmIKZBg", "uri": "/contracts/avZHGmIKZBg#pma", "label": "Collaboration Agreement (Curagen Corp)", "score": 21.0, "published": true}, {"hash": "9i46YUDd3Dv", "uri": "/contracts/9i46YUDd3Dv#pma", "label": "Collaboration Agreement (Curagen Corp)", "score": 21.0, "published": true}], "snippet": "means a Pre-Market Approval Application, 510(k) notice or similar application for marketing approval of a product for use in the Diagnostic Field submitted to the FDA, or its foreign equivalent.", "snippet_links": [{"key": "approval-application", "type": "definition", "offset": [19, 39]}, {"key": "approval-of", "type": "clause", "offset": [92, 103]}, {"key": "in-the-diagnostic-field", "type": "clause", "offset": [122, 145]}, {"key": "the-fda", "type": "clause", "offset": [159, 166]}, {"key": "foreign-equivalent", "type": "definition", "offset": [175, 193]}], "size": 8, "hash": "8d19d40730cf964c49c20e3f3c91f5f5", "id": 8}, {"samples": [{"hash": "ji0JOvM03Q4", "uri": "/contracts/ji0JOvM03Q4#pma", "label": "Investment Agreement (Avi Biopharma Inc)", "score": 21.0, "published": true}, {"hash": "4BkFt0Mm8w", "uri": "/contracts/4BkFt0Mm8w#pma", "label": "Investment Agreement (Avi Biopharma Inc)", "score": 21.0, "published": true}, {"hash": "l5vNDteLyk4", "uri": "/contracts/l5vNDteLyk4#pma", "label": "Collaborative Development Agreement (Orphan Medical Inc)", "score": 18.0, "published": true}], "snippet": "means a Premarket Approval Application as defined in 21 CFR Part 814.", "snippet_links": [{"key": "approval-application", "type": "definition", "offset": [18, 38]}, {"key": "cfr-part", "type": "clause", "offset": [56, 64]}], "size": 8, "hash": "34c69dddfca953d59ead93a8ecc685e7", "id": 9}, {"samples": [{"hash": "86amKBqlr6X", "uri": "/contracts/86amKBqlr6X#pma", "label": "Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "S0G3hH0nJ4", "uri": "/contracts/S0G3hH0nJ4#pma", "label": "Collaboration Agreement (Ambit Biosciences Corp)", "score": 24.2361392975, "published": true}, {"hash": "g4HVumm2VLo", "uri": "/contracts/g4HVumm2VLo#pma", "label": "Collaboration Agreement (Ambit Biosciences Corp)", "score": 24.1375770569, "published": true}], "snippet": "means either (i) a Premarket Approval application for a class III medical device, filed with the FDA pursuant to 21 C.F.R. \u00a7814 and Section 515 of the United States Federal Food, Drug and Cosmetic Act (\u201cFDCA\u201d), or (ii) a Premarket Notification filed with the FDA pursuant to Section 510(k) of the FDCA, each as such may be amended from time to time.", "snippet_links": [{"key": "approval-application", "type": "definition", "offset": [29, 49]}, {"key": "class-iii", "type": "definition", "offset": [56, 65]}, {"key": "medical-device", "type": "clause", "offset": [66, 80]}, {"key": "the-fda", "type": "clause", "offset": [93, 100]}, {"key": "section-515", "type": "clause", "offset": [132, 143]}, {"key": "united-states-federal", "type": "definition", "offset": [151, 172]}, {"key": "pursuant-to-section", "type": "clause", "offset": [263, 282]}, {"key": "from-time-to-time", "type": "clause", "offset": [331, 348]}], "size": 8, "hash": "8fff959c799356624b6dc98f177bb43d", "id": 10}], "next_curs": "ClASSmoVc35sYXdpbnNpZGVyY29udHJhY3RzciwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIMcG1hIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means the annual product multiplier and/or seasonal factor as appropriate for Gas Year \u201ct\u201d, in accordance with the Gas Product Multipliers and Time Factors Table.", "size": 361, "title": "PMA", "id": "pma", "examples": ["Except as otherwise provided herein, the <strong>PMA</strong> Responsible Party will be responsible for all medical device reporting, correction and removal reporting and execution of Recalls associated with any Collaboration Product, and the <strong>PMA</strong> Responsible Party will be the primary point of contact for any communications to the FDA and other Governmental Authorities, the media and customers concerning the Recall.", "Each <strong>PMA</strong> Responsible Party will promptly inform the other Party regarding the receipt or denial of <strong>PMA</strong> Approval for any Collaboration Product for which it is responsible.", "An LDT does not include an in vitro diagnostic product that has <strong>PMA</strong> Approval.", "Each <strong>PMA</strong> Responsible Party will provide the other Party with a copy of all final Regulatory Submissions for which it is responsible, and related correspondence (e.g., requests for additional information from a relevant Regulatory Authority and responses thereto), communications or meeting minutes that involve a material discussion of a Collaboration Product promptly after submission to or receipt from the relevant Regulatory Authority.", "Each <strong>PMA</strong> Responsible Party will keep the other Party reasonably informed with respect to the progress of obtaining <strong>PMA</strong> Approval of any Collaboration Product for which it is responsible.", "No later than [***] calendar days after Exact receives the first <strong>PMA</strong> Approval of a Collaboration Product for which it is the <strong>PMA</strong> Responsible Party, Exact and Freenome shall negotiate in good faith and execute a quality agreement setting forth the respective quality-related responsibilities of the Parties once each Party holds a <strong>PMA</strong> Approval for a Collaboration Product (\u201cQuality Agreement\u201d).", "Each Party, at its expense, will be responsible for the prompt review, evaluation, and documentation of all complaints relating to any Collaboration Product for which it is the <strong>PMA</strong> Responsible Party.", "Each <strong>PMA</strong> Responsible Party will provide the other Party with an opportunity to review and comment on all Regulatory Submissions relating to a Collaboration Product in the Field in the Territory for which such <strong>PMA</strong> Responsible Party is responsible and will provide such other Party with copies of all Regulatory Submissions relating to such Collaboration Products, whether first submitted to FDA prior to, on or following the Effective Date.", "Each <strong>PMA</strong> Responsible Party will consider in good faith the other Party\u2019s comments with respect thereto; provided that in no event will the <strong>PMA</strong> Responsible Party be obligated to delay the submission of any such Regulatory Submission due to such other Party\u2019s failure to provide its comments in a timely manner.", "Each Party will be responsible for complying with the FDA\u2019s medical device reporting (MDR) regulations (21 C.F.R. Part 803) and submitting any necessary reports to the FDA with respect to Collaboration Products for which it is the <strong>PMA</strong> Responsible Party."], "related": [["mfda", "MFDA", "MFDA"], ["anda", "ANDA", "ANDA"], ["pmax", "PMAX", "PMAX"], ["regulatory-approval-application", "Regulatory Approval Application", "Regulatory Approval Application"], ["nda", "NDA", "NDA"]], "related_snippets": [], "updated": "2026-04-30T06:05:53+00:00"}, "json": true, "cursor": ""}}